Lead Product(s): Filgotinib
Therapeutic Area: Gastroenterology Product Name: GS-6034
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Gilead Sciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
This latest regulatory submission is based on data from the randomized, double-blind, placebo-controlled Phase 2b/3 SELECTION study, This study showed the efficacy and tolerability of filgotinib 200 mg once daily, and no new safety risks were identified.